DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A comparative study of Neo Sampoon, Ortho Vaginal Tablets and Emko Vaginal Tablets in Accra, Ghana.

Author(s): Lamptey P, Klufio C, Smith SC, Feldblum PJ

Affiliation(s): Neo Sampoon is an effervescent contraceptive vaginal tablet manufactured in Japan that contains 60 mg of the spermicide menfegol. Ortho Vaginal Tablets (OVT) and Emko Vaginal Tablets (EVT), both containing 100 mg of the spermicide nonoxynol-9, were manufactured in the USA. The three products were compared in a randomized clinical trial conducted at the family planning clinics of the Korle-Bu Teaching Hospital and the Kotobaabi Polyclinic in Accra, Ghana. Three-hundred volunteers participated. At 12 months, the life-table pregnancy rates were 9.6, 11.3 and 12.5 per 100 women in the Neo Sampoon, OVT and EVT groups, respectively (p greater than 0.10). More EVT than Neo Sampoon or OVT users discontinued because of discomfort as well as for other product-related reasons (p less than 0.01). The most common reason for discontinuation was the temporary absence of sexual partner, with more than 40% of the women overall terminating for this reason. The 12-month life-table continuation rates per 100 women were higher for the Neo Sampoon group (62.4) than the OVT group (48.6) or the EVT group (38.5) (p less than 0.01). The effectiveness of the three products seems to be similar, but Neo Sampoon and OVT appear to be more acceptable than EVT in this Ghanaian population.

Publication date & source: 1985-11, Contraception., 32(5):445-54.

Publication type: Clinical Trial; Randomized Controlled Trial

PIP: The effectiveness and acceptability of 3 vaginal tablets (VTs)--Neo Sampoon, Ortho (OVT) and Emko (EVT)--were compared in a clinical trial conducted at the family planning clinics of Korle-Bu Teaching Hospital and Kotobaabi Polyclinic in Accra, Ghana. Subjects included 300 sexually active women ages 18-40 years who were randomly allocated to 1 of the 3 contraceptive methods. The results suggest that, although the effectiveness of the 3 tablets is comparable, Neo Sampoon and OVT are more acceptable than EVT. EVT acceptors reported poorer product compliance, more method-related complaints, and a higher rate of discontinuation. The proportion of women reporting 1 or more method-related complaints (e.g., burning or stinging) during the 1-year study period was 8.9% among Neo Sampoon acceptors, 11.5% among women in the OVT group, and 32.6% among subjects in the EVT group. However, the prevalence of these complaints, and that of increased vaginal discharge, diminished with time in all 3 study groups. Within 12 months, there had been 33 discontinuations in the Neo Sampoon group, 47 among OVT acceptors, and 57 in the EVT group. Over 40% of these discontinuations were a result of temporary absence of the sexual partner, and another 19% reflected non-method-related reasons such as desiring a pregnancy. On the other hand, discontinuation for discomfort or product-related reasons was significantly higher among EVT acceptors compared to Neo Sampoon and OVT acceptors. There were 7 unplanned pregnancies in the Neo Sampoon group (12 month cumulative pregnancy rate 9.6/100), 8 in OVT group (11.3/100), and 9 among EVT acceptors (12.5/100). 9 (38%) of the 24 pregnancies occurred in the 1st month of tablet use and only 1 pregnancy occurred 6 months or more after admission, suggesting that lack of familiarity contributed to method failure. 12-month continuation rates were significantly higher among Neo Sampoon acceptors (62.4/100) than among OVT (48.6/100) or EVT (38.5/100) acceptors.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017